Investment portfolio
Bellevue Healthcare Trust explained in 90 Seconds
Concentrated high-conviction portfolio that provides access to the global, high-growth healthcare market
Focus on companies that are making a significant contribution to the improvement of the healthcare system
The best of both worlds: Growth market and an attractive dividend yield of 3.5%
Indexed performance (as at: 21.12.2024)
Share price: GBp 137.80 (20.12.2024)
NAV: GBp 148.18 (20.12.2024)
Rolling performance (21.12.2024)
Share price | NAV | Benchmark | |
19.12.2023 - 19.12.2024 | -4.51% | -4.31% | 3.92% |
19.12.2022 - 19.12.2023 | 0.81% | 2.59% | -1.30% |
17.12.2021 - 19.12.2022 | -19.38% | -13.76% | 4.51% |
17.12.2020 - 17.12.2021 | 13.72% | 14.57% | 20.84% |
Annualized performance (21.12.2024)
Share price | NAV | Benchmark | |
1 year | -4.51% | -4.31% | 3.92% |
3 years | -8.10% | -5.40% | 2.34% |
5 years | 2.53% | 3.97% | 7.12% |
Since Inception p.a. | 7.11% | 8.31% | 9.52% |
Cumulative performance (21.12.2024)
Share price | NAV | Benchmark | |
1M | 3.21% | 1.88% | -1.55% |
YTD | -10.94% | -7.39% | 2.69% |
1 year | -4.51% | -4.31% | 3.92% |
3 years | -22.40% | -15.34% | 7.19% |
5 years | 13.32% | 21.47% | 41.07% |
Since Inception | 73.90% | 90.25% | 108.05% |
Annual performance
Share price | NAV | Benchmark | |
2023 | 6.96% | 2.39% | -1.65% |
2022 | -20.97% | -11.13% | 5.82% |
2021 | 16.56% | 15.20% | 20.83% |
2020 | 29.13% | 25.70% | 10.29% |
Facts & Key figures
Investment Focus
Bellevue Healthcare Trust intends to invest in a concentrated portfolio of listed or quoted equities in the global healthcare industry. The investable universe for the fund is the global healthcare industry including companies within industries such as pharmaceuticals, biotechnology, medical devices and equipment, Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
Investment Manager | Bellevue Asset Management (UK) Ltd. |
Custodian | Caceis Bank Luxembourg, London Branch |
Fund Administrator | NSM Funds (UK) Limited |
Auditor | Ernst & Young LLP |
Launch date | 01.12.2016 |
Year end closing | 30. Nov |
Cut of time | 17:00 UK time |
Management Fee | 0.95% |
ISIN number | GB00BZCNLL95 |
Bloomberg | BBH LN Equity |
Legal Information
Legal form | UK Investment Trust (plc) |
SFDR category | Article 8 |
Key data (30.11.2024, base currency GBP)
Beta | 1.42 |
Volatility | 29.11 |
Tracking error | 22.98 |
Active share | 77.98 |
Correlation | 0.64 |
Sharpe ratio | -0.04 |
Information ratio | -0.17 |
Jensen's alpha | -5.59 |
No. of positions | 33 |
Portfolio
Top 10 positions
Market capitalization
Geographic breakdown
Breakdown by sector
Benefits & Risks
Benefits
- Healthcare has a strong, fundamental demographic-driven growth outlook.
- The fund has a global and unconstrained investment remit.
- It is a concentrated high conviction portfolio.
- The fund offers a combination of high quality healthcare exposure and a targeted 3.5% dividend yield.
- Bellevue Healthcare Trust has a strong board of directors and relies on the experienced management team of Bellevue Asset Management (UK) Ltd
Risks
- The fund actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Healthcare equities can be subject to sudden substantial price movements owning to market, sector or company factors.
- The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- The fund may take a leverage, which may lead to even higher price movements compared to the underlying market.
Documents
Show moreShow less
These insights might interest you
I am happy to answer any questions you may have:
Investor Relations
Mark Ghahramani